Shvabe holding together with one of the leading Russian cancer centers is conducting clinical trials of DIATER-M HIFU therapy system. This is Russia’s first solution for cancer detection and non-invasive tumor removal using high intensity ultrasound.
During clinical trials, doctors will provide therapy to patients with breast tumors using DIATER-M system. HIFU is used for non-surgical tumor treatment and removal that ensures considerable reduction of rehabilitation time or patients. This method is considered to be one of the most harmless in the world. It does not need anesthesia or potent drug administration. HIFU therapy can be provided even when a patient has metal clips, various implants and surgical hardware.
The system has been developed by Novosibirsk Instrument-Making Plant (NPZ), Shvabe holding, in collaboration with Peter the Great St.Petersburg Polytechnic University. Physicians are currently given training in equipment operation.
“Clinical trial will be conducted in two stages and will last for about six months. The first trial results are to be available in summer 2024. Then, commercial production of the medical system will be started. DIATER-M is designed for treatment of benign and malignant tumors and is meant to be used in surgical units and cancer centers,” said Anton Klokov, General Director of NPZ.
